The specific aims for this collaboration are in two parts. The first deals with model development, and the second with using the model predictions.
The aims are: 1. To develop more comprehensive system models using population kinetic software tools which will include known or potential covariates (resolving kinetic variability into fixed and random effects). 2. To use the model to: (a) estimate the means, covariances and confidence limits of the basic and derived model parameters, and (b) test for model validity through the use of specific statistical tests. Unexplored yet promising applications of population -based modeling exist in the fields of occupational and environmental toxicology. The database of toxicant disposition is fragmented amongst poisoning case reports, controlled exposure studies, industrial hygiene measurements of occupational exposures, and occupational and environmental epiderniologic investigations. No modeling paradigm currently exists for the integration of such data of varying completeness and quality. The use of physiologically-based kinetic (PBK) models to study toxicant disposition, to support risk assessment and to develop occupational exposure standards is currently limited by the lack of understanding of population variability. Recent attempts to describe model variability using Monte Carlo approaches have indeterminate applicability because they use presumed parameter distributions. Moreover, the current setting of safe exposure standards is constrained by subjective weighting of heterogeneous toxicologic data. In the area of drug disposition, application of the nonlinear mixed effects modeling to population phannacokinetics has been quite valuable in the characterization of clinical populations, which is useful for the design of safe dosing regimens. A similar approach using the software tools to be developed by RFPK to create a population-based PBK model would be a powerful tool to address these needs in toxicology.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biotechnology Resource Grants (P41)
Project #
5P41RR012609-05
Application #
6569244
Study Section
Project Start
2002-03-01
Project End
2003-02-28
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Telford, Dawn E; Lipson, Sara M; Barrett, P Hugh R et al. (2005) A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content. Arterioscler Thromb Vasc Biol 25:2608-14
Dash, Ranjan K; Bell, Bradley M; Kushmerick, Martin J et al. (2005) Estimating in vitro mitochondrial oxygen consumption during muscle contraction and recovery: a novel approach that accounts for diffusion. Ann Biomed Eng 33:343-55
Dodds, Michael G; Hooker, Andrew C; Vicini, Paolo (2005) Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 32:33-64
Spilker, Mary E; Seng, Kok-Yong; Yao, Amy A et al. (2005) Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. J Magn Reson Imaging 22:549-58
Lukas, J C; Suarez, A M; Valverde, M P et al. (2005) Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. J Clin Pharm Ther 30:549-57
Welty, Francine K; Lichtenstein, Alice H; Barrett, P Hugh R et al. (2004) Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 24:1703-7
Calvo, R; Telletxea, S; Leal, N et al. (2004) Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients. Acta Anaesthesiol Scand 48:1038-48
Tannock, L R; Little, P J; Tsoi, C et al. (2004) Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia 47:837-43
Foracchia, Marco; Hooker, Andrew; Vicini, Paolo et al. (2004) POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 74:29-46
Whitfield, A J; Marais, A D; Robertson, K et al. (2003) Four novel mutations in APOB causing heterozygous and homozygous familial hypobetalipoproteinemia. Hum Mutat 22:178

Showing the most recent 10 out of 77 publications